Fourpath Capital Management’s ResMed RMD Stock Holding History

Fourpath Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$2.69K	–	645
2024 Q3	$2.69K	Buy	+11	New	+$2.46K	﹤0.01%	628

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fourpath Capital Management's RMD Position: Q4 2024 in Review

Fourpath Capital Management sold out of ResMed (RMD) in Q4 2024, closing a stake of 11 shares — an estimated $2.69K sold.

Fourpath Capital Management first reported a position in RMD in Q3 2024 and held it in 1 quarter. The position peaked at $2.69K in Q3 2024. 871 funds tracked by Wall St. Rank hold RMD as of Q4 2024.

Fourpath Capital Management reported no remaining ResMed position as of Q4 2024 after selling out during the quarter.
Fourpath Capital Management sold 11 ResMed shares in Q4 2024, an estimated $2.69K.
Fourpath Capital Management first reported a position in ResMed in Q3 2024 and held it in 1 quarter.
Fourpath Capital Management's ResMed position peaked at $2.69K in Q3 2024.
871 funds tracked by Wall St. Rank held ResMed as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.